Cargando…

Surfactant Protein A in Cystic Fibrosis: Supratrimeric Structure and Pulmonary Outcome

BACKGROUND: The state of oligomerization of surfactant associated protein-A (SP-A) monomers differs between individuals. This likely affects SP-A’s functional properties and could thereby influence clinical status in patients with lung diseases. In this study we focus on SP-A structure in cystic fib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griese, Matthias, Heinrich, Stephanie, Ratjen, Felix, Kabesch, Michael, Paul, Karl, Ballmann, Manfred, Rietschel, Ernst, Kappler, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517609/ https://www.ncbi.nlm.nih.gov/pubmed/23236429 http://dx.doi.org/10.1371/journal.pone.0051050

Ejemplares similares

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients
por: Griese, Matthias, et al.
Publicado: (2005)

In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients
por: Hector, Andreas, et al.
Publicado: (2010)

Assessment of Surfactant Protein A (SP-A) dependent agglutination
por: Heinrich, Stefanie M, et al.
Publicado: (2010)

The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients – clinical analysis of Trichosporon positive patients in a Munich cohort
por: Kröner, Carolin, et al.
Publicado: (2013)

Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy
por: Koerner-Rettberg, Cordula, et al.
Publicado: (2014)

Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
por: Perrem, Lucy, et al.
Publicado: (2020)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Letting It All Out: Neutrophils in Early Cystic Fibrosis Airway Inflammation
por: Perrem, Lucy, et al.
Publicado: (2019)

Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)
por: Papaioannou, Andriana I., et al.
Publicado: (2016)

Diabetes in Cystic Fibrosis: Multicenter Screening Results Based on Current Guidelines
por: Scheuing, Nicole, et al.
Publicado: (2013)

The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease
por: Hector, Andreas, et al.
Publicado: (2011)

Rehabilitation Programs for Cystic Fibrosis – View from a CF Center
por: Griese, M, et al.
Publicado: (2010)

Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis
por: Dumas, Marie-Pier, et al.
Publicado: (2021)

L-Ornithine Derived Polyamines in Cystic Fibrosis Airways
por: Grasemann, Hartmut, et al.
Publicado: (2012)

The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
por: Shemie, Genevieve, et al.
Publicado: (2021)

Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis
por: Grasemann, Hartmut, et al.
Publicado: (2006)

Quality of life is associated with physical activity and fitness in cystic fibrosis
por: Hebestreit, Helge, et al.
Publicado: (2014)

The effect of TGF-β(1) polymorphisms on pulmonary disease progression in patients with cystic fibrosis
por: Trojan, T., et al.
Publicado: (2022)

Novel Outcome Measures for Clinical Trials in Cystic Fibrosis
por: Tiddens, Harm AWM, et al.
Publicado: (2015)

Prognostic Relevance of Hypoglycemia Following an Oral Glucose Challenge for Cystic Fibrosis–Related Diabetes
por: Radike, Kerstin, et al.
Publicado: (2011)

High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study
por: Scheuing, Nicole, et al.
Publicado: (2014)

Lung transplantation outcome in adult surfactant-related interstitial lung disease: first evidence to move on
por: Manali, Effrosyni D., et al.
Publicado: (2023)

Surfactant proteins SP-B and SP-C and their precursors in bronchoalveolar lavages from children with acute and chronic inflammatory airway disease
por: Tafel, Oliver, et al.
Publicado: (2008)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus
por: Ballmann, Manfred, et al.
Publicado: (2014)

Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis
por: Lin, Zhenwu, et al.
Publicado: (2018)

Surfactant Lipidomics in Healthy Children and Childhood Interstitial Lung Disease
por: Griese, Matthias, et al.
Publicado: (2015)

Free DNA in Cystic Fibrosis Airway Fluids Correlates with Airflow Obstruction
por: Marcos, Veronica, et al.
Publicado: (2015)

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results
por: Bradley, Judy M., et al.
Publicado: (2014)

A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
por: Thee, Stephanie, et al.
Publicado: (2021)

Impact of COVID-19 on people with cystic fibrosis
por: Colombo, Carla, et al.
Publicado: (2020)

Getting Near to “Closing the Gap” in the Pediatric Age Group for the First Personalized Treatment of Cystic Fibrosis
por: van Koningsbruggen-Rietschel, Silke
Publicado: (2021)

Rare surfactant‐related variants in familial and sporadic pulmonary fibrosis
por: Sutton, Rachel M., et al.
Publicado: (2022)

Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease
por: Griese, Matthias, et al.
Publicado: (2005)

The surfactant protein C mutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation
por: Zarbock, Ralf, et al.
Publicado: (2012)

The Microbiome in Cystic Fibrosis Pulmonary Disease
por: Françoise, Alice, et al.
Publicado: (2020)

Acid Ceramidase Rescues Cystic Fibrosis Mice from Pulmonary Infections
por: Becker, Katrin Anne, et al.
Publicado: (2021)

Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study
por: Aaron, Shawn D., et al.
Publicado: (2012)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

Pulmonary Emphysema in Cystic Fibrosis Detected by Densitometry on Chest Multidetector Computed Tomography
por: Wielpütz, Mark O., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lntqjl7qlrkueqpfd31on5dn42